Biofield to petition FDA for product reclassification
This article was originally published in Clinica
Executive Summary
Biofield plans to petition the US FDA to reclassify its noninvasive breast cancer diagnostic system (BDS) so that the product can be cleared under the agency's simpler and shorter 510(k) regulatory pathway.